Ketamine의 용량에 따른 마취 후 떨림 예방 효과

정용관,김태요,이승우 대한마취통증의학회 2008 Korean Journal of Anesthesiology Vol.53 No.3

Background: Postanesthetic shivering affects up to 65% of patients after general anesthesia, and it can be very distressing. Various drugs have been used to treat or prevent postanesthetic shivering, but the ideal drug has not yet been found. The aim of this study was to find the minimum dose of ketamine that would show an antishivering effect. Methods: Ninety patients scheduled for total or subtotal thyroidectomy under general anesthesia were randomly allocated to three groups: Patients received saline 3 cc (Group 1; n = 30), ketamine 0.5 mg/kg (Group 2; n = 30) or ketamine 1.0 mg/kg (Group 3; n = 30) at the end of surgery. The postanesthetic shivering was evaluated by an blind investigator who was “blinded” to the dose of ketamine. The grade of shivering was assessed using a five-point scale at 0, 10, 20 and 30 minutes after the arrival to the recovery room. Results: The number of patients shivering on arrival to the recovery room, and at 10 minutes after the arrival of recovery room was significantly less in Groups 2 and 3 than in Group 1 (P < 0.05). However, at 20 and 30 minutes, the number of patients was not different among the groups. There was no difference within the groups that received ketamine. Conclusions: The prophylactic use of 0.5 mg/kg intravenous ketamine was effective in preventing shivering after general anesthesia. Background: Postanesthetic shivering affects up to 65% of patients after general anesthesia, and it can be very distressing. Various drugs have been used to treat or prevent postanesthetic shivering, but the ideal drug has not yet been found. The aim of this study was to find the minimum dose of ketamine that would show an antishivering effect. Methods: Ninety patients scheduled for total or subtotal thyroidectomy under general anesthesia were randomly allocated to three groups: Patients received saline 3 cc (Group 1; n = 30), ketamine 0.5 mg/kg (Group 2; n = 30) or ketamine 1.0 mg/kg (Group 3; n = 30) at the end of surgery. The postanesthetic shivering was evaluated by an blind investigator who was “blinded” to the dose of ketamine. The grade of shivering was assessed using a five-point scale at 0, 10, 20 and 30 minutes after the arrival to the recovery room. Results: The number of patients shivering on arrival to the recovery room, and at 10 minutes after the arrival of recovery room was significantly less in Groups 2 and 3 than in Group 1 (P < 0.05). However, at 20 and 30 minutes, the number of patients was not different among the groups. There was no difference within the groups that received ketamine. Conclusions: The prophylactic use of 0.5 mg/kg intravenous ketamine was effective in preventing shivering after general anesthesia.

HT22 세포에서 Curcumin 유도체가 Heme Oxygenase-1 발현에 미치는 효과

정용관,이윤정,천현자,류일환,지연주,채권우,김영숙,손지우,강현규,이성희,안인파,정헌택,배현옥,Cheong, Yong-Kwan,Lee, Yun-Jung,Chun, Hyun-Ja,Ryu, Il-Hwan,Jee, Yeon-Ju,Chae, Gwon-U,Kim, Young-Sook,Shon, Ji-Ue,Kang, Hyun-Gyu,Lee, Sung-Hee,An, Re 대한약학회 2011 약학회지 Vol.55 No.4

Curcumin, of which a critical characteristic is the capacity of crossing the blood-brain barrier, has been reported to induce the expression of neuroprotective heme oxygenase (HO)-1. The aim of this study is to compare HO-1-inducing capacity and neuroprotective activity of curcumin, its demethoxy (demethoxycurcumin, DMC; bis-demethoxycurcumin, BDMC) and hydrogenated derivatives (tetrahydrocurcumin, THC) in mouse hippocampal HT22 cells. Curcumin attenuated glutamate-induced cell death through HO-1 expression. DMC lacking a methoxy group on one of the aromatic rings possessed slightly lower activity in HO-1 expression and neuroprotection than curcumin. Similarly, BDMC, which lacks two methoxy groups on both of the aromatic rings, showed less activity than curcumin. These findings suggest that the presence of methoxy groups on the aromatic ring is required to enhance neuroprotective HO-1 expression. The reduction of the diarylheptadienone chain of curcumin by hydrogen, as in THC, was accompanied by a complete loss of ability to induce HO-1 expression and neuroprotection, suggesting that the conjugated double bonds of the central seven-carbon chain of curcumin may be essential for its ability to induce neuroprotective HO-1 expression. Our findings may provide useful information for further development of neuroprotective HO-1 inducers.

고식적인 치료에 반응하지 않는 대상포진 후 신경통 환자의 Magnesium 지속 정주에 의한 치료 경험 -증례보고 2예-

정용관,김태요,이주환 대한마취통증의학회 2006 Korean Journal of Anesthesiology Vol.50 No.3

Postherpetic neuralgia is one of the most troublesome diseases in pain clinics. The N-methyl-D-aspartate (NMDA) receptor antagonist, magnesium, reduces the level of neuropathic pain and hyperalgesia in patients with postherpetic neuralgia. Magnesium has been shown to exert a physiological block of the ion channel on the NMDA receptor, thereby preventing extracellular calcium ions from entering the cell and contributing to secondary neuronal changes. Accordingly, we attempted to administer a continuous intravenous infusion of magnesium, which resulted in a decrease in the VAS without side effects. (Korean J Anesthesiol 2006; 50: 361~4)

Hurler씨 증후군 환자의 마취 경험 : 증례보고

정용관,오세리,이철 圓光大學校 醫科學硏究所 2005 圓光醫科學 Vol.20 No.1

인공신경망모형을 이용한 주가의 예측가능성에 관한 연구

정용관,윤영섭 한국재무관리학회 1998 財務管理硏究 Vol.15 No.2

주가가 과연 예측가능한가의 여부는 이론적으로나 실무적으로 매우 중요한 의미를 가져 이 부분에 대해 많은 연구가 이루어져 왔으나 많은 기존연구들은 주가가 예측 가능하다는 결론을 얻지 못하고 있으며, 예측 가능하다는 연구에서도 예측력이 크지 않게 나타나고 있다. 이러한 실증결과는 실증모형의 선택이 적절하지 못한데서 나타날 수 있다는 가능성을 배제할 수 없다. 기존연구들이 실증분석에서 선형모형을 사용했는데, 선형모형으로는 주가의 예측가능성을 정확히 검증하기 어려운 현실적 요인들이 존재할 수 있다. 증권시장에는 시장실패를 방지하기 위한 규제나 제도 및 시장의 불완전성으로 인해 주가움직임에 선형모형으로 추정하기 어려운 특이패턴이 발생할 수 있기 때문이다. 이 논문에서는 이러한 특이패턴이 존재한다는 가능성을 전제로 비모수적 모형, 그 중에서도 인공신경망모형을 이용하여 주가예측 가능성을 재검증해 보고자 한다. 특히 인공신경망모형을 이용한 예측성과를 동일한 구조를 가지는 선형모형의 성과와 비교함으로써 특이패턴의 고려가 주가예측에 어떤 개선을 제공할 수 있는지를 검증해 보고자 한다. 분석결과를 요약하면, 인공신경망모형이 예측력을 가질 수 있으며, 특히 유사한 구조를 가지는 선형모형보다 우월한 성과를 제공할 수 있다는 가능성을 발견하였다. 이는 선형모형으로 추정하기 어려운 특이패턴이 주가움직임에 존재하며, 따라서 이러한 패턴을 반영할 수 있는 인공신경망모형이 주가예측에 유용하게 사용될 수 있다는 것을 보이는 결과라 볼 수 있다.

지식경제를 위한 국내 ICT투자의 현황과 문제점

정용관 한국정보화진흥원 2001 정보화정책 Vol.8 No.1

The Synergistic Effect of Intrathecally Administered Dexmedetomidine and Ketorolac on Mechanical Allodynia in Rats with Spinal Nerve Ligation

정용관,김연동,이주환,함향도,최승원,박선정 고신대학교(의대) 고신대학교 의과대학 학술지 2016 고신대학교 의과대학 학술지 Vol.31 No.2

Objectives: This research was carried out to identify the synergistic effect of dexmedetomidine and ketorolac on neuropathic pain alleviation. Methods: The anti-allodynic effect of intrathecal dexmedetomidine and ketorolac was investigated in rats after L5 spinal nerve ligation (SNL). Mechanical allodynia was assessed using Von Frey filaments. Every day for 3 consecutive days, beginning on the 10th day after SNL, behavioral tests were carried out at 1, 2, and 4 hr after drug injection. Results: Significant increases in ipsilateral paw withdrawal thresholds (PWTs) were observed 1, 2, and 4 hr after drug injection in the groups of rats which received intrathecal injection of either dexmedetomidine (group D) or ketorolac (group K), compared to group S (P < 0.05). And group DK, which received simultaneous intrathecal injection of both dexmedetomidine and ketorolac, showed statistically significantly higher ipsilateral PWTs than groups D and K, which received only one of them (P < 0.05). Conclusions: The results of this research demonstrated the anti-allodynic effect of dexmedetomidine and ketorolac on neuropathic pain induced by SNL in rats. They also suggest that synergistic analgesia can be induced by the simultaneous injection of dexmedetomidine and ketorolac, and that combination therapy is an effective approach to treating chronic neuropathic pain syndrome.

전자정부서비스의 가치평가 방법론

정용관 한국정보사회진흥원 2002 정보화정책 Vol.9 No.3

국내 초고속정보통신망의 파급효과분석에 관한 탐색적 연구

정용관,김유정 한국경영정보학회 2004 Information systems review Vol.6 No.2

환지통 환자에서 Ketamine 지속 정주에 의한 치료 경험 -증례 보고-

정용관,손용,송윤강,김태요,이철,이승우 대한통증학회 2006 The Korean Journal of Pain Vol.19 No.2

=The Trial of Continuous Intravenous Infusion of Ketaminein Patients with Phantom Limb PainA case report Yong Kwan Cheong, M.D.1, Cheol Lee, M.D.1, Yong Son, M.D.1,Yoon Kang Song, M.D.1,2, Tai Yo Kim, M.D.1,2, and Seung Woo Lee, M.D.1